Part B Self-Administered Drug Exclusions: Checking the Local Policy

When a biopharma commercial team or clinical practice learns that a subcutaneous biologic, targeted monoclonal antibody, or specialty injectable has been placed on a Medicare self-administered drug list, there is no single federal clearinghouse or master CMS spreadsheet to consult. Under the fee-for-service Medicare program, coverage for outpatient drugs administered "incident to a physician's professional service" is governed by whether the product is not usually self-administered by the patient under Sections 1861(s)(2)(A) and 1861(s)(2)(B) of the Social Security Act. Because the Centers for Medicare & Medicaid Services (CMS) delegates the administration and clinical interpretation of this statutory standard to regional Medicare Administrative Contractors (MACs), each contractor publishes its own independent Self-Administered Drug (SAD) Exclusion List within the CMS Medicare Coverage Database (MCD).

Consequently, answering whether Medicare Part B will pay for an outpatient injection requires a localized, revision-controlled verification protocol. Market-access and revenue-cycle teams must first pinpoint the physical rendering address of the administering physician, identify the governing A/B MAC jurisdiction (such as WPS in the Midwest, Noridian in the West, Novitas in the Mid-Atlantic and South Central regions, or First Coast in Florida), open that specific contractor's active MCD Coverage Article, and inspect the revision history table. Providers must cross-reference the exact Healthcare Common Procedure Coding System (HCPCS) code, verify the local effective exclusion date, apply multi-route modifier rules (such as modifier JA for intravenous infusion versus modifier JB for subcutaneous injection), and confirm whether statutory carve-outs apply. Relying on national summaries or commercial aggregators risks catastrophic claim rejections, missed 45-day transition windows, and unhedged financial liability for both practices and beneficiaries.

What the Part B Self-Administered Drug Exclusion Actually Says

The statutory architecture governing Medicare Part B drug coverage rests upon the concept of "incident to" services. Under Sections 1861(s)(2)(A) and 1861(s)(2)(B) of the Social Security Act, Medicare Part B covers drugs and biologicals that are furnished as an incident to a physician's professional service, provided they are of the kind that are commonly furnished in physicians' offices or clinics and are commonly either rendered without charge or included in the physicians' bills. Before BIPA, that statute referred to covered drugs which cannot be self-administered by the patient.

Section 112 of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA, Public Law 106-554) amended sections 1861(s)(2)(A) and 1861(s)(2)(B). The Medicare Benefit Policy Manual states that the amendment replaced the prior phrase with "not usually self-administered by the patient." Chapter 15 § 50.2 is the instruction contractors use to apply that phrase.

CMS codified the administrative interpretation of BIPA § 112 in the Medicare Benefit Policy Manual, Pub. 100-02, Chapter 15, § 50.2 ("Determining Self-Administration of Drug or Biological"). Under § 50.2, CMS establishes that "usually" means more than 50 percent of the time for all Medicare beneficiaries who use the drug. The determination is made on a drug-by-drug basis for beneficiaries as a collective whole, not as a coverage decision about one patient. People who cannot self-administer any injectable because of a condition other than the one for which they use the drug—the manual's examples are paraplegia and advanced dementia—are left out of the population used to calculate the percentage. That statistical exclusion is not an individual exception. Once the contractor determines that the drug is usually self-administered, the benefit-category denial applies without a patient-by-patient test of dexterity, vision, or cognition.

Section 50.2 uses "by the patient" to mean Medicare beneficiaries themselves. Spouses, friends, and other caregivers are not counted as the patient when the contractor builds that percentage. The contractor also ignores doses given during an inpatient stay. Administration means the physical process by which the drug enters the body. It does not turn on whether a professional watches technique or side effects, and preparing a pen or kit is not itself that act.

When a drug has more than one indication, § 50.2 tells the contractor to decide self-administration separately for each indication and then weight those results by each indication's share of total use. The manual's example is a drug with three indications: it is not self-administered for the first indication, which accounts for 40 percent of use, and it is self-administered for the second and third, which account for 30 percent each. That drug is treated as usually self-administered. The result is one determination for the drug, not a separate Part B rule for each indication and not a set of invented claim shares.

To streamline claims adjudication, CMS manual guidelines establish evidentiary presumptions based on the physical route of administration:

• Intravenous (IV) Infusions: Absent evidence to the contrary, drugs delivered intravenously are presumed not usually self-administered. The presumption is not a payment guarantee. Incident-to rules, medical necessity, and any row already on the SAD list still apply.

• Intramuscular (IM) Injections: Absent evidence to the contrary, intramuscular drugs are presumed not usually self-administered. The manual's example is Avonex. The contractor may consider the depth and nature of the particular injection.

• Subcutaneous (SC) Injections: Absent evidence to the contrary, subcutaneous drugs are presumed self-administered. The contractor still looks at the facts for that drug, including whether the condition is acute and how often the injection is given. A monthly injection is less likely to be self-administered than one given once a week or more often.

• The Acute Course Rule: For this test, an acute condition begins over a short period and is expected to be short. A course of scheduled injections lasting less than two weeks, whatever the frequency or route, is considered acute. Acute use makes self-administration less likely. It does not by itself make the dose payable under Part B.

• Physical Administration Boundary: The manual limits "administered" to the physical process by which the drug enters the patient's body. Supervision of technique or monitoring for side effects is not administration. Reconstituting a vial, priming a pen, or assembling a kit is not that physical act either.

How a MAC Decides a Drug Is 'Usually Self-Administered'

Under the decentralized structure of Medicare Part B, the authority to evaluate drugs against the 50 percent standard is assigned directly to individual A/B Medicare Administrative Contractors. Chapter 15 § 50.2 requires each contractor to develop, document, and publish the exact evidentiary process it utilizes to make SAD determinations. Contractors cannot issue informal or unwritten coverage bars; every exclusion must be anchored in verified data and formal contractor governance.

When a contractor reviews an outpatient drug, Chapter 15 § 50.2 requires it to consider these sources. They are the required evidence, not a ranked hierarchy, and the contractor may also consider other material submitted by interested people or groups:

1. Peer-Reviewed Medical Literature: Published clinical studies, observational registries, and real-world evidence evaluating how and where patients receive the medication.

2. Standards of Medical Practice: Established care protocols documented across academic medical centers and professional specialty societies.

3. Evidence-Based Practice Guidelines: Formal clinical practice recommendations issued by national medical associations (such as the American College of Rheumatology, American Gastroenterological Association, or American Academy of Dermatology).

4. FDA-Approved Labeling and Package Inserts: The formal prescribing information, dosage and administration instructions, and patient instructions for use (IFU).

An FDA package insert that describes self-administration shows that self-administration is feasible. Under § 50.2 it is not, by itself, the reason a drug goes on the exclusion list. Before August 1, 2002, self-administration instructions on the label were a principal factor. The manual now says that fact is not independently determinative. A boxed warning or an observation requirement is evidence the contractor may weigh with the other required sources. It is not a separate rule that keeps a drug off the list, and it is not a promise of Part B payment.

CMS expects contractors to review injectable drugs on a rolling basis and to update the exclusion list no less than annually. The manual also requires notice 45 days before the listed drugs will not be covered. During those 45 days the contractor maintains existing medical review and payment procedures. After the notice period it may deny payment. The claim follows the effective date on that contractor's article. Publishing the pending change on the contractor website and in the Medicare Coverage Database, with the rationale for the determination, is part of the same duty. The notice window is the time for a clinic or hub to confirm the row and decide whether a later date of service has to leave Part B buy-and-bill.

Why There Is No National List: The MAC Jurisdiction Map

A persistent trap for national health systems and biopharma launch planners is the assumption that Medicare maintains a unified, centralized self-administered drug directory. In reality, Part B claims administration is divided among regional commercial insurance carriers operating under contract with CMS as A/B MACs. Because each contractor conducts independent literature reviews, evaluates regional claims data, and establishes its own committee calendars, the resulting SAD exclusion lists are geographically fragmented.

This structural fragmentation was formally acknowledged by CMS in the CY 2024 Physician Fee Schedule proposed rule (88 FR 52262, published August 7, 2023), where the agency noted that each MAC maintains its own list applicable strictly to its jurisdiction, and that contractor lists are "often similar but not identical." A subcutaneous drug may be evaluated, placed on 45-day notice, and excluded by WPS in the Midwest months before Novitas or Noridian takes regulatory action, or contractors may arrive at differing conclusions regarding the adequacy of self-administration data.

To verify coverage for a specific provider, access teams must identify the contractor managing the physical state where the service is rendered, access the corresponding MCD Article, and consult the active revision:

Those five articles are the records behind the worked examples below. They are not the entire A/B MAC map. National Government Services publishes article A53021, CGS Administrators publishes A52527, and Palmetto GBA publishes A53066. A claim rendered in Illinois, Ohio, or North Carolina is not answered by the WPS, Noridian, Novitas, or First Coast article. Open the article for the contractor that pays the claim, then read that article's version table before using any date in this piece.

Understanding this contractor map is critical when evaluating commercial data aggregators. Third-party tools such as BuyandBill.com republish CMS Coverage API data (listing, for example, 151 excluded entries across 58 HCPCS codes under WPS as of September 2026). While helpful as a preliminary screening mechanism, vendor mirrors often lag primary contractor publications by weeks, fail to display pending 45-day notice notices, and carry explicit disclaimers regarding data accuracy. For audit-proof reimbursement compliance, revenue cycle teams must verify the dated table row in the primary MCD Article.

The Check, Step by Step: From Provider Address to a Dated Table Row

To eliminate payment denials and properly align benefit routing between pharmacy and medical channels, access specialists should execute a rigorous five-step verification protocol for every provider-administered injectable:

1. Step 1: Map the Provider's Physical Rendering Location. Medicare Part B claims are processed according to the physical facility where the injection is administered, not the patient's legal state of residence or the manufacturer's headquarters. Identify the physical ZIP code and confirm the administering A/B MAC jurisdiction.

2. Step 2: Access the MAC's Specific SAD Article in the Medicare Coverage Database. Open the Medicare Coverage Database and the article for the contractor that pays the claim. The articles used for the examples below are A52800 (WPS), A53032 (Noridian JE), A53033 (Noridian JF), A53127 (Novitas), and A52571 (First Coast). Other A/B MAC articles include A53021 (National Government Services), A52527 (CGS), and A53066 (Palmetto).

3. Step 3: Inspect the Article Version History and Revision Status. Open the article version history. Compare the date of service with the effective date on the revision that applies, including a future-effective row. During the 45-day notice period the contractor keeps existing payment procedures, and it may deny the drug after that period. Do not treat a guessed day count as a substitute for the effective date printed on the article.

4. Step 4: Locate the Specific HCPCS / CPT Code and Stated Rationale. Search the article's coding tables for the permanent HCPCS code (e.g., J-code, Q-code) or unclassified code (J3490, J3590, C9399). Confirm whether the drug entry matches the exact brand, generic name, dosage form, and clinical rationale.

5. Step 5: Apply Route Modifiers (JA vs. JB) and Asterisk Rules. Examine whether the code carries an asterisk (*) or special coding footnote. For multi-route products, MACs require modifier JA for intravenous infusion and modifier JB for subcutaneous injection. Verify whether modifier JA protects the infusion from denial, and check whether unclassified billing is explicitly prohibited.

flowchart TD
  A["Clinic plans an outpatient injectable"] --> B["Identify the site where the drug is administered"]
  B --> C["Map that site to its A/B MAC article"]
  C --> D["Open that article in the Medicare Coverage Database"]
  D --> E["Read the version table and the effective date"]
  E --> F{"Is the HCPCS row on the SAD exclusion table?"}
  F -- "No" --> G["Not on this list: still apply incident-to rules and medical necessity"]
  F -- "Yes" --> H{"Does the row use a dual-route asterisk?"}
  H -- "Yes" --> I{"Which route was furnished?"}
  I -- "Intravenous" --> J["Append JA; JA does not waive incident-to or medical-necessity rules"]
  I -- "Subcutaneous" --> K["Append JB: Part B benefit-category denial"]
  H -- "No" --> L["Part B benefit-category denial; no ABN is required"]
  K --> M["Part D or another benefit is a separate coverage check"]
  L --> M

Worked Records From the 2026 Revisions

Analyzing recent 2026 contractor revisions provides concrete evidence of how cross-MAC timing divergence, biosimilar entries, and coding footnotes create operational friction for commercialization and reimbursement teams.

A prime illustration of effective-date divergence occurred in late summer 2026 with the IL-17A/IL-17F antagonist bimekizumab (Bimzelx). Noridian JE article A53032, Revision 47, added bimekizumab-bkzx under J3490, J3590, and C9399 effective August 29, 2026. The same August 29, 2026 row date appears for Bimzelx on the CMS-sourced WPS A52800 list. Novitas A53127 Revision 31 and First Coast A52571 Revision 34 added the same three unclassified codes effective August 30, 2026. J0565 is injection, bezlotoxumab, 10 mg, not a bimekizumab code. On August 29, the Novitas and First Coast exclusions were not yet effective, while the Noridian JE exclusion was. That is a one-day difference in the exclusion effective date. It is not a finding that every August 29 dose in Texas or Pennsylvania was otherwise payable.

Those August revisions also added Starjemza (Q5164). Noridian JE Revision 47 added Q5164 effective August 29, 2026, and the WPS list carries the same row date. Novitas Revision 31 and First Coast Revision 34 added Q5164 effective August 30, 2026, and both revision notes say an asterisk was added to Q5164 for the JA and JB modifiers. An asterisk is a route-modifier instruction. It is not a statement that every Starjemza claim is denied the same way, and it is not automatic parity with reference Stelara. Separately, nemolizumab (Nemluvio) was added by Novitas and First Coast under C9399, J3490, and J3590 for dates of service on or after June 15, 2026. Other contractors can use a different June date. Read each article rather than copying those two.

Modifier footnotes have to be read against the route named in the note. First Coast and Novitas both record that, for dates of service on or after April 30, 2026, the asterisk was removed from risankizumab-rzaa (Skyrizi) for subcutaneous injection, listed with C9399, J3490, and J3590, because those listings no longer require JA or JB. The note is not a retroactive processing rule for older dates of service, and it does not say intravenous loading doses became payable. Removing the asterisk means the JA/JB split no longer applies to that subcutaneous unclassified listing. It does not take the listing off the exclusion table.

Revision history also shows corrections and deletions that are easy to misread as new coverage decisions:

• Teriparatide (Forteo, HCPCS J3110): Noridian posted Jurisdiction E article A53032 Revision 46 on June 4, 2026. The notice adds J3110, injection, teriparatide, 10 mcg, back to the SAD list because a prior revision had removed it in error. The effective date on that notice is September 16, 2013, not a new exclusion that starts in June 2026. A 2026 posting date does not mean the drug left the list until 2026.

• Furosemide Subcutaneous (Furoscix, HCPCS J1941): Noridian JE article A53032 Revision 48, posted and effective October 1, 2026, deleted J1941, injection, furosemide (Furoscix), 20 mg. Noridian JF article A53033 Revision 49 deleted the same code effective October 1, 2026. Deleting an exclusion-table row is not an affirmative Part B payment decision. Incident-to rules still apply, and another contractor's article can still list the code.

• GLP-1 Incretin Therapies: Incretin injectables already appear on contractor SAD lists under codes and dates that differ by article. A listing produces a Part B benefit-category denial for that contractor. It does not place the product on a Part D formulary, and it does not mean every semaglutide or tirzepatide code is treated the same way in every jurisdiction.

What Exclusion Changes Downstream: Denials, ABNs and Benefit Routing

The operational consequences of placing a drug on a MAC SAD exclusion list extend far beyond simple claim rejections. Because the exclusion derives from statutory benefit definitions rather than clinical judgment, it triggers unique billing and liability rules that catch unprepared practices.

First and foremost, a SAD denial is a benefit-category exclusion under Section 1861(s)(2) of the Act, not a medical-necessity denial under Section 1862(a)(1)(A). This distinction governs patient financial liability:

• No Mandatory ABN: Under CMS Benefit Policy Manual Chapter 15 § 50.2, an Advance Beneficiary Notice of Noncoverage (ABN, Form CMS-R-131) is not legally required for a benefit-category denial. The manual requires an ABN when the denial is based on medical necessity, not when there is no benefit category. Issuing a voluntary ABN does not change that characterization, and failing to issue one does not create coverage. The older Notice of Exclusion from Medicare Benefits is not the current instrument.

• Inapplicability of Limitation on Liability: The statutory protections of Section 1879 of the Social Security Act ("Limitation on Liability of Beneficiary Where Medicare Claims Disallowed") do not apply. Under Section 1879, if a provider fails to issue an ABN for a medically unnecessary service, the provider must absorb the financial loss and cannot bill the beneficiary. In contrast, for a SAD exclusion denial, the provider is legally entitled to bill the Medicare beneficiary directly for the excluded drug. The manual does not set that charge at 100 percent of an amount the provider chooses.

• Beneficiary Appeal Rights: Although Section 1879 protections are absent, Medicare beneficiaries retain full administrative appeal rights. If a patient or clinic believes a MAC improperly classified a drug as usually self-administered, they may challenge the claim denial through standard redetermination, reconsideration, and Administrative Law Judge (ALJ) appeal levels.

Chapter 15 § 50.2 also limits when a hospital may bill the beneficiary. If a drug in the hospital outpatient department is an integral part of a procedure, or directly related to performing or recovering from it, Medicare treats the drug as a packaged supply. Except for the applicable copayment, the hospital may not bill the beneficiary for that drug. The manual's examples include sedatives in a preoperative area, drops used for an eye procedure, and contrast media used for imaging. Drugs the patient will keep using at home, a routine home medication given before surgery, and treatment that is the drug itself rather than a supply to a procedure are not packaged that way. A SAD listing and this packaged-supply rule answer different questions. The practice still has to know which setting billed the dose.

To prevent billing workarounds, MAC claims processing systems enforce automatic filters on unclassified codes. Providers cannot bypass a SAD listing by billing unclassified drug codes such as HCPCS J3490 (Unclassified drugs), J3590 (Unclassified biologics), or C9399 (Unclassified drugs or biologicals). MAC articles explicitly instruct claims adjudicators to inspect invoice descriptions and NDC numbers; when an unclassified claim corresponds to a SAD-listed product, it is summarily denied.

Access teams must also evaluate the statutory carve-outs that can survive a SAD exclusion. Self-administration does not defeat these categories, but each one still has its own statutory conditions:

1. Blood Clotting Factors: Section 1861(s)(2)(I) covers blood clotting factors (such as Factor VIII and Factor IX) for hemophilia patients competent to self-administer in home settings.

2. Transplant Immunosuppressive Drugs: Section 1861(s)(2)(J) covers immunosuppressive drugs following an organ transplant paid by Medicare, including expanded lifetime coverage under the Part B Immunosuppressive Drug Benefit (Part B-ID) established by the Consolidated Appropriations Act of 2021.

3. Erythropoietin (EPO) for Dialysis: Section 1861(s)(2)(O) covers erythropoietin for dialysis patients who are competent to use the drug without medical or other supervision, subject to the Secretary's safety standards. Section 1881(b)(11)(B) is a different provision: it keeps erythropoietin out of the ESRD prospective payment bundle and sets separate payment. It is not the benefit-category citation.

4. Oral Anti-Cancer Chemotherapeutic Agents: Section 1861(s)(2)(Q) covers oral anti-cancer drugs that have the same active ingredient and clinical indication as an injectable or IV chemotherapy agent.

5. Oral Anti-Emetic Drugs: Section 1861(s)(2)(T) covers oral anti-emetics prescribed as a full therapeutic replacement for IV anti-emetics administered within 48 hours of chemotherapy.

6. Osteoporosis drugs for certain homebound patients. Chapter 15 § 50 names this group with the other self-administered drugs the statute can still cover. The manual does not spell the eligibility limits out in § 50.2, so the check is the specific osteoporosis-drug benefit, not the SAD article alone.

A separate benefit uses the same lists. Home infusion therapy has its own drug definition. 42 CFR § 486.505, which Chapter 15 § 320.7 restates, defines a home infusion drug as a parenteral drug or biological administered intravenously, or subcutaneously for 15 minutes or more, in the individual's home through a durable medical equipment pump. The definition excludes insulin pump systems and a self-administered drug or biological on a self-administered drug exclusion list. Adding a product to the contractor's SAD list removes it from that definition. Chapter 15 § 320.7 treats qualifying home infusion drugs as durable medical equipment supplies to a covered pump, and it treats the home infusion therapy services payment as a separate professional benefit. A SAD listing does not itself approve either payment.

When a drug is excluded from Part B, the primary payment mechanism pivots to Medicare Part D. However, access teams must recognize that Part D coverage is neither automatic nor seamless. Commercial teams navigating pharmacy benefit lockout and medical-to-pharmacy route shifts must verify individual Part D plan formularies, navigate specialty tier cost-sharing, and submit required prior authorization and step-therapy documentation. As detailed in our analysis of PBM formulary management and coverage tiers, Part D plans maintain independent utilization controls that require dedicated case management.

Where Access Teams Get Caught

In commercial launch planning and ongoing practice revenue-cycle operations, access teams routinely stumble over five preventable failure modes:

1. Relying on National Clearinghouse Aggregators: Treating third-party lookup tools or vendor mirrors as real-time compliance records. Aggregators often homogenize distinct regional effective dates or fail to capture mid-month MAC revisions.

2. Overlooking the 45-Day Advance Notice Window: Failing to monitor the "Future Effective" section of MCD version tables. Clinics that do not track pending additions continue purchasing expensive buy-and-bill inventory, only to administer it after the exclusion takes effect, triggering immediate claim rejections and severe buy-and-bill margin losses.

3. Mismanaging Dual-Route Asterisk Codes (JA vs. JB): Failing to append modifier JA when billing intravenous formulations of dual-route products, or inadvertently submitting modifier JB for subcutaneous injections, resulting in automatic claims processing denials.

4. Miscalculating Interim Billing Timelines: Failing to account for the interplay between unclassified codes and new permanent J-codes. As examined in our guide to J-code timing and interim billing risk, billing an unclassified code for a SAD-listed drug during the launch window triggers instant payment rejection.

5. Assuming Part D Coverage Parity: Assuming that exclusion from Part B automatically opens frictionless Part D fulfillment. Patients frequently face unexpected prior authorization rejections, formulary tier placement hurdles, and deductible exposure in the outpatient pharmacy channel.

The Policy Debate and What Would Change the Check

The administrative mechanics of the Medicare Part B self-administered drug exclusion are subject to intensifying scrutiny from clinical specialty societies, patient advocacy organizations, and federal policy makers. In the CY 2024 Physician Fee Schedule proposed rule (88 FR 52262, published August 7, 2023), CMS issued a formal Request for Information (RFI) regarding drugs that are "not usually self-administered." The agency solicited public feedback on whether the 50 percent threshold remains clinically appropriate, how newly approved complex therapeutics should be evaluated, and whether contractor revision processes should be standardized.

What happened after that request is narrower than a rewrite of the manual:

• Center for Medicare Advocacy: Advocacy organizations emphasized that the collective, population-level standard deprives vulnerable beneficiaries of necessary clinical care. Patients with severe physical deformities, advanced neuromuscular disease, or severe visual impairment who cannot self-inject are denied Part B incident-to coverage simply because healthier beneficiaries self-administer at home, exposing frail seniors to thousands of dollars in out-of-pocket costs without individual medical review.

• CY 2024 final rule comments: The CY 2024 Physician Fee Schedule final rule, published November 16, 2023, summarized comments on self-administered drugs. Commenters addressed appeals, FDA labeling, caregivers, and patients who cannot self-administer. That comment summary did not replace Chapter 15 § 50.2. Arguments from physician groups about Part D specialty-tier cost sharing are stakeholder positions unless a primary document measures them.

• February 2026 Multi-Specialty Coalition Petition: On February 19, 2026, a prominent coalition of medical specialty societies led by the American Society for Gastrointestinal Endoscopy (ASGE) submitted a formal petition urging CMS to reform the SAD exclusion policy. The coalition requested that CMS permit Part B coverage when physician administration is determined to be clinically necessary. To support their case, the coalition cited findings from the Department of Health and Human Services Office of Inspector General (OIG) demonstrating that following the addition of ustekinumab (Stelara) to MAC SAD lists, Medicare program spending on the drug escalated dramatically from approximately $300 million in 2016 to nearly $3 billion in 2023. The coalition argued that SAD listings shift massive financial burdens onto the Part D catastrophic coverage phase without generating meaningful systemic savings.

For pharmaceutical commercialization and market-access teams, understanding this debate is critical, but operational compliance must remain anchored in current law. The local, revision-controlled verification protocol outlined in this dossier remains the governing standard. A structural shift in the verification check would require concrete federal regulatory action:

1. A Formal CMS Manual Transmittal: CMS would need to issue a formal transmittal revising Pub. 100-02, Chapter 15 § 50.2, redefining the 50 percent standard or introducing clinical exception criteria.

2. A National Coverage Determination (NCD): CMS could issue a binding NCD establishing uniform national coverage conditions for specific therapeutic drug classes.

3. Federal Notice-and-Comment Rulemaking: Finalized regulatory revisions in the annual Physician Fee Schedule establishing new coding structures or administrative pathways for complex provider-administered injectables.

Until CMS codifies such federal reforms, market-access and clinical reimbursement teams must continue executing the local verification check: identifying the governing A/B MAC, auditing the active MCD Coverage Article, respecting the 45-day notice timeline, and routing claims to Part D before the local exclusion window closes.

Sources

1. Medicare Benefit Policy Manual, Pub. 100-02, Chapter 15 — Covered Medical and Other Health Services, §§50–50.2 (Drugs and Biologicals; Self-Administered Drugs) — Centers for Medicare & Medicaid Services (Accessed 2026-10-01).

2. Self-Administered Drug Exclusion List (SAD List) — MCD Article A52800, WPS — CMS Medicare Coverage Database (WPS Insurance Corporation, A/B MAC J5/J8) (Accessed 2026-10-01).

3. Self-Administered Drug Exclusion List — MCD Article A53032, Noridian JE — CMS Medicare Coverage Database (Noridian Healthcare Solutions, A/B MAC Jurisdiction E) (Accessed 2026-10-01).

4. Self-Administered Drug Exclusion List — MCD Article A53127, Novitas JH/JL — CMS Medicare Coverage Database (Novitas Solutions, A/B MAC Jurisdictions H and L) (Accessed 2026-10-01).

5. Self-Administered Drug Exclusion List — MCD Article A52571, First Coast Service Options JN — CMS Medicare Coverage Database (First Coast Service Options, A/B MAC Jurisdiction N) (Accessed 2026-10-01).

6. Self Administered Drugs (SADs) — Noridian JE Part B policy page — Noridian Healthcare Solutions (Medicare Administrative Contractor) (Accessed 2026-10-01).

7. Medicare and Medicaid Programs; CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (proposed rule, includes SAD RFI) — Federal Register / Centers for Medicare & Medicaid Services (Accessed 2026-10-01).

8. CMS Request for Information Regarding Self-Administered Drugs — Center for Medicare Advocacy Calls for Reform — Center for Medicare Advocacy (Accessed 2026-10-01).

9. Groups Ask CMS to Change Self-Administered Drug Exclusion Policy (ASGE, February 19, 2026) — American Society for Gastrointestinal Endoscopy (The Advocate) (Accessed 2026-10-01).

10. Self-Administered Drug (SAD) Exclusion List — BuyandBill.com republication — BuyandBill.com (Accessed 2026-10-01).